Research Presentation Session
RPS 516 - CT in oncology
Lectures
1
RPS 516 - Incidence, risk factors and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer
05:29F. Cousin, Liège / Belgium
2
RPS 516 - Multiparametric functional imaging in lung cancer: the importance of tumour radiomic heterogeneity beyond FDG PET/CT and lung biopsy
04:10T. Polidori, Rome / Italy
3
RPS 516 - Skeletal muscle mass and skeletal muscle radiodensity: two sides of the same medal or two different medals?
04:57L. Weerink, Almelo / Netherlands
4
RPS 516 - The prognostic significance of radiomic features from chest CT in advanced non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation receiving second-line osimertinib treatment
04:02Xin Tang, Chengdu / China
5
RPS 516 - Orbital metastases: common pathologies and imaging pearls
04:36J. O'Mahony, Dublin / Ireland
6
RPS 516 - CT based radiomic approach on first line Pembrolizumab in lung cancer
04:25E. Lucertini, Rome / Italy
7
RPS 516 - Dosimetry and biokinetic modelling of thyroid cancer patients treated with radioiodine as part of an international multi-centre study within MEDIRAD
04:50Jan Taprogge, Sutton / UK
8
RPS 516 - Dual-energy CT assessment of skeletal bone marrow involvement in multiple myeloma
05:03R. Gu, London / UK
9
RPS 516 - Development of perfusion CT and its importance for evaluating pancreatic diseases: a quantitative meta-analysis
04:58N. Vats, Heidelberg / Germany